Form 4: Amicus Therapeutics CEO Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley L. Campbell, executed a pre-planned transaction involving the exercise of stock options and the sale of common stock.
Summary
- Amicus Therapeutics CEO, Bradley L. Campbell, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share on December 2, 2024.
- On the same day, Mr. Campbell sold 7,500 shares of common stock at a weighted average price of $10.0166 per share, with individual sales ranging from $10.00 to $10.06.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
- Following these transactions, Mr. Campbell directly owns 886,654 shares of Amicus Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not indicate any change in the company's fundamentals. It is a routine filing.
Risks
- The sale of shares by the CEO could be perceived negatively by some investors, although it was part of a pre-planned trading strategy.
Industry Context
This type of transaction is common for executives who receive stock options as part of their compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Amicus Therapeutics.
- Similar transactions are frequently seen at companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals, where executives regularly exercise stock options and sell shares as part of their compensation and financial planning.
- The reported price range of $10.00 to $10.06 for the share sale is within the typical market fluctuations observed for companies of this size and sector.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, but the pre-planned nature of the sale should mitigate any negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/23/2023 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 12/02/2024 | Date of the stock option exercise and share sale. |
| 12/03/2024 | Date the Form 4 was signed. |
| 01/02/2025 | Expiration date of the stock options. |
Keywords
Amicus Therapeutics, Bradley L. Campbell, stock options, share sale, Rule 10b5-1, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.